-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Upgrades Alnylam Pharmaceuticals to Strong Buy, Maintains Price Target to $420

Benzinga·08/03/2026 18:48:24
Listen to the news
Raymond James analyst Martin Auster upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Outperform to Strong Buy and maintains the price target from $420 to $420.